Double cross-linked fibrin gel, raw material composition thereof, kit, and use thereof
A double-crosslinked fibrin gel with optimized fibrin and photosensitive networks addresses adhesion and coagulation issues, providing rapid and effective hemostasis by forming fibrin aggregates and photocurable gels, suitable for diverse bleeding sites.
Patent Information
- Application Number
- JP2024538770
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-12
- Filing Date
- 2023-08-17
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2043-08-17
AI Technical Summary
Current hemostatic agents face challenges with poor adhesion to wet tissues, limited hemostatic efficacy, and slow coagulation times, especially in severe bleeding scenarios, due to issues with fibrin glue washout and synthetic adhesives' cytotoxicity and difficulty in removal.
A double-crosslinked fibrin gel comprising a three-dimensional fibrin network and a photosensitive gel network, optimized with a volume ratio of 0.5 to 3, which rapidly forms fibrin aggregates and photocurable gel to enhance adhesion and coagulation, using methacryloylated polymers and enzymatic crosslinking.
The gel achieves rapid hemostasis with strong adhesion to wet tissues, preventing fibrin washout and promoting efficient coagulation, suitable for various bleeding sites including liver, spleen, and skin.
Smart Images

Figure 2024544346000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biomedical materials, and in particular to a double cross-linked fibrin gel for hemostasis of accidental trauma or surgical bleeding, and a method for using the same. [Background technology]
[0002] Uncontrolled bleeding after trauma or during surgery is a leading cause of death worldwide, causing more than 2 million deaths each year. Uncontrolled bleeding during surgery and trauma often leads to complications and adverse outcomes. Controlling bleeding is therefore an important measure to reduce complications and mortality and improve patient outcomes.
[0003] At present, several topical hemostatic materials have been developed to help control bleeding during surgery. Commonly used surgical sealants on the market include fibrin glue and synthetic tissue adhesives. Fibrin glue is the most widely used hemostatic agent with excellent biocompatibility, which can assist hemostasis in various surgical procedures, simulate the coagulation cascade reaction, form fibrin clots in situ at the bleeding site, and block bleeding. However, fibrin glue loses adhesive strength due to continuous tissue tension and blood, and is easily washed away by blood flow, which is unfavorable to the exertion of its hemostatic function, and its hemostatic effect is limited due to its low adhesive strength to wet tissue. Meanwhile, synthetic tissue adhesives such as cyanoacrylate glues, despite their excellent adhesive ability, are limited in their use due to their high cytotoxicity and difficult removal.
[0004] In order to break the bottleneck of the current use of bioadhesives, which is the low adhesive strength of bioadhesives on the surface of wet tissues, the prior art has been researching the use of methacryloylated gelatin as a hemostatic gel material. Such double-bond modified gelatin is obtained by functionalizing the free amino of gelatin with methacrylic anhydride to form methacrylamide groups. Under the condition of irradiation with a certain wavelength, the photoinitiator in the material absorbs light energy to generate free radicals, which form bonds between the molecules of methacryloylated gelatin to form a solid gel. In addition to having excellent biocompatibility, methacryloylated gelatin also has excellent mechanical properties and adhesive strength. However, methacryloylated gelatin does not have a coagulation-promoting function, which limits its hemostatic ability to a certain extent. Methacryloylated gelatin has a long photocuring time of 5 to 10 seconds and is easily washed away by blood flow during the photocuring process, so in severe bleeding, a large amount of blood weakens its adhesive ability. In the study by Luo et al., to compensate for this drawback, hemocoagulase with coagulation function was introduced into methacryloyl gelatin, and the hemostatic gel constructed thereby had improved hemostatic effect. (Guo Y, Wang Y, Zhao X, et al. Snake extract-laden hemostatic bioadhesive gel cross-linked by visible light. Sci Adv. 2021. 7(29).). However, in the methacryloyl gelatin carrying hemocoagulase constructed in this study, only a very small amount of hemocoagulase on the surface of the gel can come into contact with blood, and the concentration of fibrinogen in blood is low (2-4 g / L), and the formed fibrin crosslinks are insufficient to close the wound. In addition, methacryloyl gelatin has a weak effect of closing the wound before light curing is completed. All of these significantly limit its hemostatic effect.In 2020, Wang et al. incorporated free thrombin and thrombin-loaded liposomes into methacryloylated gelatin to construct a thrombin-methacryloylated gelatin hydrogel that promotes hemostasis through early thrombin release and regulates late multi-stage healing of diabetic wounds through sustained thrombin release (Chongyang W, Tianyi W, Guangwang L, et al. Promoting coagulation and activating SMAD3 phosphorylation in wound healing via a dual-release thrombin-hydrogel. Chemical Engineering Journal. 2020. 397(C).). The disadvantages of the gel constructed in this study are similar to those of Luo et al. The amount of thrombin released from the gel is small, and it has little contact with fibrinogen in the blood, which means it cannot form fibrin bridges, resulting in a weak wound-closing effect and a reduced hemostatic effect.
[0005] In addition, the prior art also reports that other photocurable materials are used to manufacture hemostatic materials. For example, Chinese patent document CN111116973A discloses a polyvinyl alcohol hemostatic porous material with active hemostatic function, in which a polymer with active hemostatic function such as chitosan or (and) thrombin is added to a sponge obtained by photocatalytic crosslinking of modified polyvinyl alcohol, thereby imparting an active hemostatic effect to the sponge. However, the hemostatic time reported in this paper is 90s-100s, and the hemostatic time is long and the hemostatic effect is inevitably reduced. This is because 1) the pre-formed sponge cannot fully contact the wet tissue, so the closure effect is inferior to that of the gel formed in situ, 2) the thrombin in the sponge is not easily liberated in the dry state, so its coagulation promotion function is limited, and 3) the concentration of fibrinogen in blood is low (2-4g / L), and the formed fibrin crosslinks are insufficient to close the wound. Therefore, when a large amount of bleeding occurs during surgery, it is difficult to meet the demand for rapid hemostasis. In addition, when there is a wound on an organ or the body surface that is bleeding, the expansion of the sponge limits the action and effect of compressing the wound, weakening the hemostatic effect to a certain extent. In addition, when the sponge is removed, the sponge may adhere to the hemostatic area, causing secondary damage to the wound.
[0006] A suitable hemostatic material should be independent of the body's clotting mechanism, should be able to exert hemostatic effects even when the body's clotting mechanism fails, should have a high adhesive ability to wet tissue, and should have a suitable rate of coagulation and hemostatic activity. Therefore, it is particularly important to invent a new hemostatic material that can solve the problems of existing hemostatic materials, such as poor adhesive strength to wet tissue and limited hemostatic effect. Summary of the Invention [Problem to be solved by the invention]
[0007] In order to solve the above-mentioned shortcomings in the prior art, the main object of the present invention is to provide an adhesive that can achieve both the effects of promoting coagulation and improving adhesion, thereby enabling rapid hemostasis and rapid gelation, and having high adhesive properties.
[0008] Another object of the present invention is to provide a raw material composition capable of preparing said adhesive, and a kit for clinical dissemination and use of said adhesive.
[0009] A further object of the present invention is to provide a method for stopping bleeding using the kit. [Means for solving the problem]
[0010] In order to achieve the above objectives, the present invention adopts the following technical solutions:
[0011] In a first aspect, the present invention provides a double-crosslinked fibrin gel, which is a solid hydrogel composed of a network structure having a closing function and a network structure having an adhesive function, and the network structure having a closing function is formed prior to the network structure having an adhesive function. The network structure having a closing function is a three-dimensional fibrin network, and the network structure having an adhesive function is a three-dimensional photosensitive gel network, each of the photosensitive gel network channels has a set of the fibrin networks, each set of the fibrin networks is generally continuous, and the three-dimensional fibrin network is generally randomly distributed over the surface and the interior of the solid hydrogel.
[0012] In the double crosslinked fibrin gel of the present invention, the three-dimensional fibrin network functions as a scaffold and enhances the strength of the gel, and its formation process converts fibrinogen in blood into fibrin, thereby performing the function of preliminary closure of the wound. As the proportion of fibrin increases, the gelation time of the solid hydrogel is shortened, the adhesion to tissue decreases, but the pores of the gel become larger, and the pro-clotting function improves. The three-dimensional photosensitive gel network serves to impart strength and adhesion to tissue to the gel. As the proportion of photosensitive gel network in the solid hydrogel increases, the adhesion to tissue of the solid hydrogel also increases, but the gelation time also increases, the pores of the gel become smaller, and the pro-clotting function decreases. Considering the different effects of the above two networks on the overall hemostatic performance of the gel, the present invention further optimized the proportions of the two networks in the gel through experiments. In a preferred double cross-linked fibrin gel, the volume ratio of the three-dimensional fibrin network to the three-dimensional photosensitive gel network is 0.5 to 3, preferably 0.5 to 2, and most preferably 1. At these optimal volume ratios, the two networks provide excellent hemostatic performance to the entire gel, and in particular, when the volume ratio of the fibrin network to the photosensitive gel network reaches 1:1, the hemostatic performance of the gel is optimal, and clotting can be rapidly promoted while improving the strength and adhesive force of the gel.
[0013] In the double-crosslinked fibrin gel of the present invention, the photosensitive gel can be formed by photocrosslinking of various existing photocurable polymeric materials (i.e., photosensitive materials). The photosensitive material may be a methacryloyl polymer or a derivative thereof, a polyacrylate polymer or a derivative thereof, or a polymer composite material system containing them.
[0014] Furthermore, the methacryloylated high molecular weight polymer or its derivative may be any one or mixture of two or more selected from methacryloylated gelatin or its derivative, methacryloylated hyaluronic acid or its derivative, methacryloylated sodium alginate or its derivative, methacryloylated silk fibroin or its derivative, methacryloylated chitosan or its derivative, and methacryloylated carboxymethyl chitosan or its derivative. The polyacrylate high molecular weight polymer or its derivative may be selected from polyether diacrylate or its derivative, or polyethylene glycol diacrylate or its derivative. The most preferred photosensitive material of the present invention is methacryloylated gelatin or its derivative, or methacryloylated silk fibroin or its derivative.
[0015] Furthermore, the derivatives of the methacryloylated high molecular weight polymer include a polymer modified at one or more of its functional groups. The functional groups that can be modified of the methacryloylated gelatin include any one or more of amino, carboxy, mercapto, hydroxy, or guanidino. The derivatives of the methacryloylated hyaluronic acid include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or more of hydroxy, carboxy, acetamide, or hydroxymethyl. The derivatives of the methacryloylated sodium alginate include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or two of carboxy and hydroxy. The derivatives of the methacryloylated silk fibroin include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or two of amino, carboxy, mercapto, hydroxy, or guanidino. The derivatives of methacryloylated chitosan include polymers having one or more functional groups modified or undergoing multiple chemical reactions, where the functional groups that can be modified include any one or more of amino or hydroxy, and the multiple chemical reactions that can occur include any one or more of alkylation, acylation, carboxymethylation, hydrolysis, oxidation, and reduction chemical reactions.
[0016] The molecular weight of the methacryloylated high molecular weight polymer or its derivative is in the range of 5 to 400 kDa, and the molecular weight of the polyacrylate high molecular weight polymer or its derivative is in the range of 700 to 1000 kDa.
[0017] Further, the polymer composite material system containing the methacryloylated polymer or its derivative includes a methacryloylated gelatin-polyvinyl alcohol system, a methacryloylated gelatin-polyurethane system, a methacryloylated gelatin-polylactic acid system, a methacryloylated gelatin-cellulose system, a methacryloylated hyaluronic acid-polyvinyl alcohol system, a methacryloylated hyaluronic acid-polyurethane system, a methacryloylated hyaluronic acid-polylactic acid system, a methacryloylated hyaluronic acid-cellulose system, a methacryloylated sodium alginate-polyvinyl alcohol system, a methacryloylated sodium alginate-polyurethane system, a methacryloylated sodium alginate-polylactic acid system, a methacryloylated sodium alginate-cellulose system, The present invention includes one or more of methacryloylated silk fibroin-polyvinyl alcohol systems, methacryloylated silk fibroin-polyurethane systems, methacryloylated silk fibroin-polylactic acid systems, methacryloylated silk fibroin-cellulose systems, methacryloylated chitosan-polyvinyl alcohol systems, methacryloylated chitosan-polyurethane systems, methacryloylated chitosan-polylactic acid systems, methacryloylated chitosan-cellulose systems, methacryloylated carboxymethyl chitosan-polyvinyl alcohol systems, methacryloylated carboxymethyl chitosan-polyurethane systems, methacryloylated carboxymethyl chitosan-polylactic acid systems, and methacryloylated carboxymethyl chitosan-cellulose systems.
[0018] In the double-crosslinked fibrin gel of the present invention, the fibrin network may be formed by enzymatic crosslinking of fibrinogen. The fibrinogen may be any one of human fibrinogen, bovine fibrinogen, and porcine fibrinogen.
[0019] In a second aspect, the present invention provides a raw material composition for preparing the double crosslinking fibrin adhesive according to the first aspect of the present invention, comprising composition A and composition B, wherein composition A comprises 10 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, and composition B comprises 5 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen, and the mass ratio of composition A to composition B is 1.4:10 to 14:1, preferably 1.4:1 to 1.4:10, more preferably 1.4:1 to 1.4:5, and most preferably 1.4:1.
[0020] In a preferred embodiment of the invention, the weight part of the photosensitive material in composition A is greater than the weight part of the photosensitive material in composition B. The above weight parts of the photosensitive materials in composition A and composition B are advantageous for the enzyme in composition A and the fibrinogen in composition B to undergo an enzymatic reaction to form a stabilized fibrin network.
[0021] In the raw material composition of the present invention, the fibrinogen can form a fibrin network through an enzymatic crosslinking reaction by the action of the enzyme, and the photosensitive material can form a photosensitive gel through a photocrosslinking reaction by the action of the photoinitiator. Therefore, a double crosslinked fibrin adhesive can be prepared by mixing composition A and composition B in the raw material composition of the present invention in the above mass ratio and then irradiating them with light. This adhesive is a solid hydrogel, and both a three-dimensional fibrin network and a three-dimensional photosensitive gel network exist in its structure. There is a set of the fibrin networks in each of the photosensitive gel network channels, and each set of the fibrin networks is continuous as a whole. The three-dimensional fibrin network exists in a disordered manner on the surface and inside of the solid hydrogel as a whole. When this solid hydrogel is formed on a bleeding wound, it instantly (about 1s) forms a fibrin clot on the surface of the wound, which acts to preliminarily close the wound and prevent blood from leaking out. In addition, the enzyme in the fibrin clot converts fibrinogen in the blood into a clot, thereby performing an efficient coagulation promotion function. Moreover, under photoexcitation, the photosensitive material can form a photocurable gel within 5 to 10 s. The photocurable gel has high adhesive strength, can withstand the impact of blood flow, and prevents fibrin crosslinks from being washed away by blood. In short, in the raw material composition of the present invention, after the composition A and the composition B are mixed, a fibrin network serving as a scaffold is immediately formed, and then a photosensitive gel is also quickly formed. The fibrin network is covered by the photosensitive gel formed later.
[0022] In the present invention, it was found through experiments that the mass ratio of the composition A to the composition B in the raw material composition is related to the effect of pre-clotting the wound and the adhesive strength of the double cross-linked fibrin adhesive. When the mass ratio of the composition A to the composition B is in the range of 1.4:10 to 1.4:1, as the ratio of the composition A increases, the coagulation-promoting function of the double cross-linked fibrin adhesive increases, the effect of pre-clotting the wound increases, and the adhesive strength increases. When the mass ratio of the composition A to the composition B is in the range of 1.4:1 to 14:1, as the ratio of the composition A increases, the coagulation-promoting function of the double cross-linked fibrin adhesive, the effect of pre-clotting the wound, and the adhesive strength do not increase any more. This means that when the mass ratio of the composition A to the composition B is 1.4:1, the best hemostatic effect can be achieved and the best utilization rate of the material can be achieved. At this ratio, the volume ratio of the two networks generated by cross-linking reaches about 1:1, which can provide the prepared gel with the optimal coagulation-promoting function and adhesive strength.
[0023] In a preferred raw material composition of the present invention, composition A contains 80 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, and composition B contains 30 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0024] In a more preferred raw material composition of the present invention, composition A contains 100 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, and composition B contains 30 to 50 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0025] In the most preferred raw material composition of the present invention, composition A contains 100 to 150 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, and composition B contains 30 to 50 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0026] In a third aspect, the present invention also provides a method for preparing the raw material composition, comprising the steps of preparing a mixed solution in which a photosensitive material and a photoinitiator are dissolved in a solvent, mixing the mixed solution with a solution containing hemopexin and calcium ions to obtain a first precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, the enzyme, and the calcium ions in the first precursor solution to 10-200:1-3:0.14-0.28:1.11-8.88, and mixing the mixed solution with a solution containing fibrinogen to obtain a second precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, and the fibrinogen in the second precursor solution to 5-100:1-2:30-50, thereby obtaining a liquid raw material composition containing the first precursor solution and the second precursor solution. The liquid raw material composition may be further processed by a conventional method to obtain a solid raw material composition such as a freeze-dried powder, a sponge, or a granule.
[0027] In the preparation method of the present invention, the time for leaving the first precursor solution in a room temperature environment is controlled to be less than 30 minutes in order to maintain the activity of the photosensitive material in the first precursor solution.
[0028] In the preparation method of the present invention, it is preferable to control the concentration of the photosensitive material in the first precursor solution to be higher than 0.5% (w / v) and the concentration of the photosensitive material in the second precursor solution to be lower than the concentration of the photosensitive material in the first precursor solution, taking into consideration the uniformity of the dispersion of fibrinogen and the photocrosslinking speed of the photosensitive material. Thereby, the fibrinogen solution is more easily and uniformly dispersed in the second precursor solution containing a relatively low concentration of the photosensitive material. When the two precursor solutions are well mixed, they come into contact with the enzyme quickly and completely, and immediately undergo complete enzyme crosslinking to form a uniformly distributed fibrin network. In addition, when the concentration of the photosensitive material in the first precursor solution is high, the concentration of the entire photosensitive material mixed with the two precursor solutions is increased, which is a more ideal concentration required for gelation, which is favorable for shortening the photocrosslinking time and improving the adhesion and strength of the gel.
[0029] In the preparation method of the present invention, when the first precursor solution and the second precursor solution are prepared, the temperature of the mixed solution is preferably controlled to 37° C. or lower.
[0030] A more preferred method for preparing the raw material composition injection of the present invention is specifically, Step 1) of preparing a first mixed solution by dissolving a photosensitive material and a photoinitiator in a solvent, and controlling the concentration ratio of the photosensitive material to the photoinitiator to 10-200:1-3 and the concentration of the photosensitive material to 0.5%-30% (w / v); Step 2) of preparing a second mixed solution by dissolving a photosensitive material and a photoinitiator in a solvent, and controlling the concentration ratio of the photosensitive material to the photoinitiator to be 5 to 100:1 to 2 and the concentration of the photosensitive material to be lower than that of the first mixed solution described in step 1); 3) mixing the first mixed solution prepared in 1) with a solution containing an enzyme and calcium ions to obtain a first precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, the enzyme, and the calcium ions to 10-200:1-3:0.14-0.28:1.11-8.88; and step 4) mixing the second mixed solution prepared in step 2) with a solution containing fibrinogen to obtain a second precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, and the fibrinogen to 5-100:1-2:30-50.
[0031] In the preparation method of the present invention, the solution containing the enzyme and calcium ions is prepared by adding a solvent and a water-soluble inorganic calcium salt solution to the enzyme, dissolving it completely and forming a Ca 2+ The enzyme activity in the obtained solution is 500IU-2000IU / ml, Ca 2+ The concentration is preferably controlled to 60 to 100 mmol / L.
[0032] In the preparation method of the present invention, the concentration of fibrinogen in the fibrinogen-containing solution is preferably 5% to 10% (w / v).
[0033] In a preferred preparation method of the present invention, the concentration of the photosensitive material in the first precursor solution is controlled to 1% to 30% (w / v), more preferably 8% to 30% (w / v), and even more preferably 10% to 20%.
[0034] In a preferred preparation method of the present invention, the enzyme activity in the first precursor solution is controlled to 200 IU / ml or more, preferably 500 IU / ml or more, more preferably 1000 IU / ml or more.
[0035] In a preferred preparation method of the present invention, the concentration of calcium ions in the first precursor solution is controlled to 20 mmol / L or more, preferably 30 mmol / L or more, more preferably 40 mmol / L or more.
[0036] In a preferred preparation method of the present invention, the concentration of the photosensitive material in the second precursor solution is controlled to be 0.5% (w / v) or more and not more than the concentration of the photosensitive material in the first precursor solution, more preferably 1% (w / v) or more and not more than the concentration of the photosensitive material in the first precursor solution, and more preferably 1% to 10% (w / v) and not more than the concentration of the photosensitive material in the first precursor solution.
[0037] In a preferred preparation method of the present invention, the concentration of fibrinogen in the second precursor solution is controlled to 3% (w / v) or more, more preferably 3% to 5% (w / v).
[0038] In a fourth aspect, the present invention also provides a kit for preparing a double crosslinked fibrin gel according to the first aspect of the present invention, comprising a first precursor reagent and a second precursor reagent packaged individually from each other, the first precursor reagent containing 10 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 3.33 to 5.55 parts by weight of a water-soluble inorganic calcium salt, and the second precursor reagent containing 5 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen, and the mass ratio of the first precursor reagent to the second precursor reagent is 1.4:10 to 14:1, preferably 1.4:1 to 1.4:10, more preferably 1.4:1 to 1.4:5, and most preferably 1.4:1.
[0039] In a preferred kit of the present invention, the first precursor reagent contains 80 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 3.33 to 5.55 parts by weight of a water-soluble inorganic calcium salt, and the second precursor reagent contains 30 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0040] In a more preferred kit of the present invention, the first precursor reagent contains 100 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 3.33 to 5.55 parts by weight of a water-soluble inorganic calcium salt, and the second precursor reagent contains 30 to 50 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0041] In the most preferred kit of the present invention, the first precursor reagent contains 100 to 150 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 3.33 to 5.55 parts by weight of a water-soluble inorganic calcium salt, and the second precursor reagent contains 30 to 50 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
[0042] In the kit of the present invention, the photosensitive material contained in the first precursor reagent and the second precursor reagent is a photosensitive biohydrogel material, and may be any of various existing photocurable polymer materials. The photoinitiator contained in the first precursor reagent and the second precursor reagent is a substance that absorbs light energy and generates free radicals under the condition of irradiation with light of a specific wavelength. The photoinitiator can absorb light energy and generate free radicals, which form bonds between the molecules of the photosensitive material, thereby rapidly forming a solid gel. A suitable photosensitive material should have good biocompatibility and degradability, as well as good mechanical and adhesive properties.
[0043] In the raw material composition or kit of the present invention, the photosensitive material may be a methacryloylated high molecular weight polymer or a derivative thereof, a polyacrylate high molecular weight polymer or a derivative thereof, or a polymer composite material system containing these.
[0044] Furthermore, the methacryloylated high molecular weight polymer or its derivative may be any one or mixture of two or more selected from methacryloylated gelatin or its derivative, methacryloylated hyaluronic acid or its derivative, methacryloylated sodium alginate or its derivative, methacryloylated silk fibroin or its derivative, methacryloylated chitosan or its derivative, and methacryloylated carboxymethyl chitosan or its derivative. The polyacrylate high molecular weight polymer or its derivative may be selected from polyether diacrylate or its derivative, or polyethylene glycol diacrylate or its derivative. The most preferred photosensitive material of the present invention is methacryloylated gelatin or its derivative, or methacryloylated silk fibroin or its derivative.
[0045] Furthermore, the derivatives of the methacryloylated high molecular weight polymer include a polymer modified at one or more of its functional groups. The functional groups that can be modified of the methacryloylated gelatin include any one or more of amino, carboxy, mercapto, hydroxy, or guanidino. The derivatives of the methacryloylated hyaluronic acid include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or more of hydroxy, carboxy, acetamide, or hydroxymethyl. The derivatives of the methacryloylated sodium alginate include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or two of carboxy and hydroxy. The derivatives of the methacryloylated silk fibroin include a polymer modified at one or more of its functional groups, and the functional groups that can be modified include any one or two of amino, carboxy, mercapto, hydroxy, or guanidino. The derivatives of said methacryloylated chitosan include polymers having one or more of its functional groups modified or undergoing multiple chemical reactions, where the functional groups that can be modified include any one or two of amino or hydroxy, and the multiple chemical reactions that can occur include any one or more of alkylation, acylation, carboxymethylation, hydrolysis, oxidation, and reduction chemical reactions.
[0046] The molecular weight of the methacryloylated high molecular weight polymer or its derivative is in the range of 5 to 400 kDa, and the molecular weight of the polyacrylate high molecular weight polymer or its derivative is in the range of 700 to 1000 kDa.
[0047] Further, the polymer composite material system containing the methacryloylated polymer or its derivative includes a methacryloylated gelatin-polyvinyl alcohol system, a methacryloylated gelatin-polyurethane system, a methacryloylated gelatin-polylactic acid system, a methacryloylated gelatin-cellulose system, a methacryloylated hyaluronic acid-polyvinyl alcohol system, a methacryloylated hyaluronic acid-polyurethane system, a methacryloylated hyaluronic acid-polylactic acid system, a methacryloylated hyaluronic acid-cellulose system, a methacryloylated sodium alginate-polyvinyl alcohol system, a methacryloylated sodium alginate-polyurethane system, a methacryloylated sodium alginate-polylactic acid system, a methacryloylated sodium alginate-cellulose system, The present invention includes one or more of methacryloylated silk fibroin-polyvinyl alcohol systems, methacryloylated silk fibroin-polyurethane systems, methacryloylated silk fibroin-polylactic acid systems, methacryloylated silk fibroin-cellulose systems, methacryloylated chitosan-polyvinyl alcohol systems, methacryloylated chitosan-polyurethane systems, methacryloylated chitosan-polylactic acid systems, methacryloylated chitosan-cellulose systems, methacryloylated carboxymethyl chitosan-polyvinyl alcohol systems, methacryloylated carboxymethyl chitosan-polyurethane systems, methacryloylated carboxymethyl chitosan-polylactic acid systems, and methacryloylated carboxymethyl chitosan-cellulose systems.
[0048] In the preferred raw material composition or kit of the present invention, the photoinitiator may be any one or more compositions selected from lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, ethyl 2,4,6-trimethylbenzoylphenylphosphinate, 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one, methyl 2-benzoylbenzoate, 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)butanone, or 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide], and is most preferably lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate.
[0049] In the preferred raw material composition or kit of the present invention, the enzyme may be any one selected from human thrombin, recombinant human thrombin, bovine thrombin, porcine thrombin, and hemocoagulase.
[0050] In the preferred raw material composition or kit of the present invention, the fibrinogen may be any one selected from human fibrinogen, bovine fibrinogen, and porcine fibrinogen.
[0051] In a preferred raw material composition or kit of the present invention, the water-soluble inorganic calcium salt may be selected from calcium chloride, calcium nitrate, or calcium sulfate, but is most preferably calcium chloride.
[0052] In a preferred kit of the present invention, the first precursor reagent and / or the second precursor reagent further comprises an auxiliary material and / or an additive. The auxiliary material is one or more selected from glycine, arginine hydrochloride, sodium citrate, sucrose, and sodium chloride. The additive is one or more selected from growth factors, interleukins, vitamins, and silver ions. The growth factor may further be one or more selected from platelet growth factor, epidermal growth factor, or fibroblast growth factor, the interleukin may further be one or more selected from interleukin 2, interleukin 6, or interleukin 8, and the vitamin may further be one or more selected from vitamin B, vitamin C, vitamin E, or vitamin K.
[0053] In the kit of the present invention, the first precursor reagent and / or the second precursor reagent may be in a number of specific dosage forms that are pharma- ceutically or clinically acceptable, such as a lyophilized powder, a sponge, or a granule.
[0054] The kit of the present invention may further include a preparation solvent that is individually packaged, and the preparation solvent may be any one or a mixture of a plurality of phosphate buffer solution, HEPES biological buffer solution, 0.9% sodium chloride solution, calcium chloride solution, and deionized water. The dosage form of the preparation solvent is preferably an injection.
[0055] The kit of the present invention may further comprise an instruction manual that describes how to use the kit.
[0056] In a fifth aspect, the present invention also provides a method for performing on-site rapid hemostasis on a bleeding wound using the kit according to the fourth aspect of the present invention, the method comprising: preparing the first precursor reagent and the second precursor reagent into an injectable solution using a preparation solvent, respectively, and uniformly injecting or spraying the first precursor reagent and the second precursor reagent into the bleeding wound; and then irradiating the bleeding wound with light in a wavelength range of 290 to 480 nm for 10 to 60 s to rapidly form a solid hydrogel in situ at the bleeding wound.
[0057] The bleeding wound includes organ bleeding caused by accidental trauma or during surgery, the organ may be the liver, spleen, kidney, gastrointestinal tract, heart, or skin.
[0058] In the above-mentioned use of the present invention, when the kit is injected into a bleeding wound, (1) it can instantly (about 1 s) form a fibrin clot on the surface of the wound, which can preliminarily close the wound and prevent blood from flowing out, thereby strengthening the weak closure effect of the photosensitive material until the completion of photocuring. (2) In addition, the enzyme in the fibrin clot can convert fibrinogen in the blood into a clot, which can perform an efficient coagulation promotion function. (3) Furthermore, under photoexcitation, the photosensitive material can form a photocurable gel within 5 to 10 s. The photocurable gel has high adhesive strength, can withstand the impact of blood flow, and can prevent the fibrin crosslinks from being washed away by blood. Therefore, by preparing a double-crosslinked fibrin gel on-site using the above-mentioned kit or kit of the present invention, a double-crosslinked fibrin gel having a structure of fibrin crosslinked network and photocrosslinked network can be obtained by combining the fast generation speed of fibrin crosslinks and the high adhesive strength due to photocrosslinking. Effect of the Invention
[0059] Compared with the prior art, the advantages of the present invention are: short gelation time, fast setting speed, strong adhesion to wet tissue, and good hemostatic effect. (1) The double cross-linked fibrin gel kit of the present invention generates fibrin cross-links immediately (about 1 s) after mixing, which plays a preliminary sealing role and blocks the impact of blood flow. (2) The enzyme in the double cross-linked fibrin gel kit of the present invention can convert fibrinogen in blood into fibrin cross-links, and has efficient coagulation promoting ability. (3) The double-crosslinked fibrin gel kit of the present invention can undergo a photocrosslinking reaction within 5 to 10 seconds under excitation by ultraviolet or visible light to form a photocurable gel, which imparts high adhesive strength to wet tissue and prevents the fibrin crosslinks from being washed away by blood. The double cross-linked fibrin gel according to the present invention has an excellent coagulation promoting function, a fast solidification rate, high adhesive strength to wet tissues, and a rapid hemostatic effect, and can therefore be used in hemostatic applications for the treatment of bleeding from the liver, spleen, kidneys, heart, gastrointestinal tract, and skin in accidental trauma or surgery. [Brief description of the drawings]
[0060] [Figure 1] 1 is an SEM image of fibrin crosslinks in Comparative Example 1. [Diagram 2] 1 is an SEM image of photocrosslinking of methacryloylated gelatin in the precursor solution of Comparative Example 2. [Diagram 3] 1 is an SEM image of the double cross-linked fibrin gel of Example 1. [Figure 4] The hemostasis time in Examples 1, 9, 14, 19, 25, and 31 and Comparative Examples 1 to 6 was compared. [Diagram 5] The amount of blood loss in Examples 1, 9, 14, 19, 25, and 31 and Comparative Examples 1 to 6 was compared. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0061] The technical problems to be solved by the present invention, the technical solutions and the beneficial effects thereof will be described in detail below with reference to specific examples. The following examples are intended to help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any way. However, those skilled in the art may make some modifications and improvements without departing from the concept of the present invention. These fall within the scope of protection of the present invention.
[0062] The present invention provides a double-crosslinked fibrin gel, which is a solid hydrogel composed of both a three-dimensional photosensitive gel network and a three-dimensional fibrin network. The double-crosslinked fibrin gel has a microstructure shown in FIG. 3, and has both a fibrin crosslinked network structure and a photosensitive material crosslinked porous structure. Within each channel of the porous structure, there is a set of the fibrin networks, each set of the fibrin networks is generally continuous, and the three-dimensional fibrin network is generally randomly present across the surface and interior of the solid hydrogel. The fibrin network functions as a scaffold for the photosensitive gel network channels, and the pore walls of the photosensitive gel porous structure surround the fibrin network structure.
[0063] The double-crosslinked fibrin gel is prepared by the following method. (1) Preparation of composition A solution: An enzyme solution containing calcium ions is dissolved in a mixed solution in which a photosensitive material and a photoinitiator are dissolved, and the mixture is mixed uniformly to obtain a composition A solution containing a photosensitive material, a photoinitiator, and an enzyme. The concentration of the photosensitive material in the obtained composition A solution is controlled to 1% (w / v) or more, preferably 3% (w / v) or more, more preferably 3% to 20% (w / v), and the enzyme activity is controlled to 200 IU / mL or more, preferably 500 IU / mL or more, more preferably 1000 IU / mL or more. (2) Preparation of composition B solution: A fibrinogen solution is added to a mixed solution in which a photosensitive material and a photoinitiator are dissolved, and mixed uniformly to obtain a composition B solution containing a photosensitive material, a photoinitiator, and fibrinogen. The concentration of the photosensitive material in the obtained composition B solution is controlled to 0.5% (w / v) or more, preferably 1% to 10% (w / v), and the concentration of fibrinogen is controlled to 3% (w / v) or more, preferably 3% to 5% (w / v). (3) Storage method: The obtained Composition A solution and Composition B solution are each freeze-dried in a volume ratio of 1:10 to 10:1, and stored in a sponge-like form. (4) Preparation of double cross-linked fibrin gel using the above freeze-dried sponge: Sponge-like component A and sponge-like component B were dissolved in a solvent, respectively, to obtain injectable solution-like components A and B. The component A solution and component B solution were uniformly injected / sprayed at the bleeding site in equal volumes, and irradiated with blue light or ultraviolet light for 10 to 60 s to rapidly form a solid hydrogel in situ. As a preferred form, the injection device used when using the injectable solution is a double syringe, a syringe, or a Pasteur pipette. In the above preparation form, the solvent may be any one or a combination of a phosphate buffer solution, a HEPES biological buffer solution, a 0.9% sodium chloride solution, a calcium chloride solution, and deionized water, and the amount used is not particularly limited and can be prepared according to the actually required concentration. Based on the above embodiments, the present invention will be further illustrated by the following examples. EXAMPLES
[0064] The method for preparing the double cross-linked fibrin gel in this example includes the following steps: (1) Preparation of methacryloylated gelatin-lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate precursor solution: A desired volume of 0.9% sodium chloride solution was added to powdered lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate and dissolved by heating in a water bath to obtain two concentrations of lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate solutions (0.25% (w / v), 0.5% (w / v)). The desired concentration of lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate solution was added to the desired weight of solid methacryloylated gelatin, and dissolved by heating in a water bath to obtain two mass volume percentage (w / v) precursor solutions of methacryloylated gelatin-lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate: 26% (w / v) methacryloylated gelatin-0.5% (w / v) phenyl(2,4,6-trimethylbenzoyl)phosphinate and 10% (w / v) methacryloylated gelatin-0.25% (w / v) phenyl(2,4,6-trimethylbenzoyl)phosphinate. (2) Preparation of hemopexin solution: A calcium chloride solution of a desired volume and concentration was injected into hemopexin and completely dissolved to obtain a hemopexin solution with a hemopexin activity of 2000 IU / mL. 2+ The concentration is 80mmol / L. (3) Preparation of fibrinogen solution: A desired weight of fibrinogen was slowly added to preheated 0.9% sodium chloride solution until completely dissolved, yielding a 10% (w / v) fibrinogen solution. (4) Preparation of component A solution: The hemopexin solution obtained in step (2) was added to the precursor solution of 26% (w / v) methacryloylated gelatin-0.5% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate obtained in step (1) and mixed uniformly to obtain component A solution: 13% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate-1000 IU / mL hemopexin. (5) Preparation of component B solution: The fibrinogen solution obtained in step (3) was added to the precursor solution of 10% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate obtained in step (1) and mixed uniformly to obtain component B solution: 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate-5% (w / v) fibrinogen. (6) Storage: The obtained component A solution and component B solution were each freeze-dried in a volume ratio of 1:1 and stored in a sponge-like form. (7) Method of use: The sponge-like A and B components were dissolved in a 0.9% sodium chloride-containing solution at a volume ratio of 1:1 to obtain injectable solutions of A and B components. The A and B solutions were placed in equal volumes in a double syringe, and the A and B solutions were injected / sprayed into the bleeding site using a nozzle. After irradiation with blue light for 10-60 s, a solid hydrogel was formed in situ. The volume ratio of fibrin crosslinks to photocrosslinks in the gel obtained in this way was 1:1. (8) The structure of the solid gel is shown in Figure 3. This is a solid hydrogel composed of both a 3D fibrin network and a 3D photosensitive gel network, where a set of the fibrin networks is present inside the porous structure of the crosslinked methacryloylated gelatin formed, each set of the fibrin networks is generally continuous, and the 3D fibrin network is generally present in a disordered manner on the surface and inside of the solid hydrogel. EXAMPLES
[0065] A mixed solution of 10% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method were the same as those of Example 1, except that the concentration of methacryloylated gelatin in the component A solution prepared in step (4) was adjusted to 10% (w / v). EXAMPLES
[0066] A mixed solution of 8% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method were the same as those of Example 1, except that the concentration of methacryloylated gelatin in the component A solution prepared in step (4) was adjusted to 8% (w / v). EXAMPLES
[0067] A mixed solution of 5% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method of the component A solution prepared in step (4) were the same as those of Example 1, except that the concentration of methacryloylated gelatin in the component A solution was 5% (w / v). In the gel obtained in this manner, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0068] A mixed solution of 13% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 3% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method were the same as those of Example 1, except that the concentration of methacryloylated gelatin in the component B solution prepared in step (5) was adjusted to 3% (w / v). EXAMPLES
[0069] A mixed solution of 13% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The composition, preparation method, and usage method of the component solution A prepared in step (4) were the same as those of Example 1, except that the hemopexin activity of the component solution A was adjusted to 500 IU / mL. EXAMPLES
[0070] A mixed solution of 13% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-250 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The composition, preparation method, and usage method of the component solution A prepared in step (4) were the same as those of Example 1, except that the hemopexin activity of the component solution A was adjusted to 250 IU / mL. EXAMPLES
[0071] A mixed solution of 13% (w / v) methacryloyl gelatin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl gelatin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method of the component B solution prepared in step (5) were the same as those of Example 1, except that the concentration of fibrinogen in the component B solution was 3% (w / v). In the gel obtained in this manner, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2. EXAMPLES
[0072] A mixed solution of 8% (w / v) methacryloylated hyaluronic acid, 0.25% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, and 1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloylated hyaluronic acid, 0.125% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, and 5% (w / v) fibrinogen was prepared as component solution B. The preparation and use method were the same as in Example 1, except that: 1. In this example, the photosensitive material in components A and B was methacryloylated hyaluronic acid, and the concentration of methacryloylated hyaluronic acid in the component A solution was 8% (w / v); 2. The preparation of the precursor solution of methacryloylated hyaluronic acid-lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate did not require heating and could be carried out at room temperature. In the gel thus obtained, the volume ratio of fibrin crosslinks to photocrosslinks was 1:1. EXAMPLES
[0073] A mixed solution of 5% (w / v) methacryloyl hyaluronic acid-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl hyaluronic acid-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. Except for the concentration of methacryloyl hyaluronic acid in component A solution being adjusted to 5% (w / v), its composition, preparation method, and usage method were the same as those in Example 9. In the gel thus obtained, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0074] A mixed solution of 8% (w / v) methacryloyl hyaluronic acid-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000IU / mL hemopexin was prepared as component A solution, and a mixed solution of 3% (w / v) methacryloyl hyaluronic acid-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. Except for adjusting the concentration of methacryloyl hyaluronic acid in component B solution to 3% (w / v), its composition, preparation method, and usage method were the same as those in Example 9. EXAMPLES
[0075] A mixed solution of 8% (w / v) methacryloyl hyaluronic acid-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500IU / ml hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl hyaluronic acid-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. Except that the hemopexin activity of component A solution was adjusted to 500IU / ml, its composition, preparation method, and usage method were the same as those of Example 9. EXAMPLES
[0076] A mixed solution of 8% (w / v) methacryloyl hyaluronic acid-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl hyaluronic acid-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. Except for adjusting the concentration of fibrinogen in component B solution to 3% (w / v), its composition, preparation method, and usage method were the same as those in Example 9. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2. EXAMPLES
[0077] A mixed solution of 8% (w / v) methacryloylated sodium alginate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated sodium alginate-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. In this example, the photosensitive material in components A and B was sodium methacryloylated alginate, and the preparation and use methods were the same as those in Example 9. In the gel thus obtained, the volume ratio of fibrin crosslinking to photocrosslinking was 1:1. EXAMPLES
[0078] A mixed solution of 5% (w / v) methacryloylated sodium alginate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated sodium alginate-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method of the component A solution were the same as those of Example 14, except that the concentration of methacryloylated sodium alginate in the component A solution was adjusted to 5% (w / v). In the gel obtained in this manner, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0079] A mixed solution of 8% (w / v) methacryloyl sodium alginate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 3% (w / v) methacryloyl sodium alginate-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The concentration of methacryloyl sodium alginate in component B solution was adjusted to 3% (w / v), and the composition, preparation method, and usage method were the same as those in Example 14. EXAMPLES
[0080] A mixed solution of 8% (w / v) methacryloyl-modified sodium alginate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloyl-modified sodium alginate-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The hemopexin activity in component solution A was adjusted to 500 IU / mL, and the composition, preparation method, and usage method were the same as those in Example 14. EXAMPLES
[0081] A mixed solution of 8% (w / v) methacryloyl-modified sodium alginate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl-modified sodium alginate-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. The concentration of fibrinogen in component B solution was adjusted to 3% (w / v), and its composition, preparation method, and usage method were the same as those in Example 14. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2. EXAMPLES
[0082] A mixed solution of 10% (w / v) methacryloylated silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloylated silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. In this example, the photosensitive material in components A and B was methacryloylated silk fibroin, and the concentration of methacryloylated silk fibroin in component A solution was 10% (w / v), except that the preparation method and use method were the same as those in Example 9. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:1. EXAMPLES
[0083] A mixed solution of 8% (w / v) methacryloyl silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloyl silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The concentration of methacryloyl silk fibroin in component solution A was adjusted to 8% (w / v), and the composition, preparation method, and usage method were the same as those in Example 19. EXAMPLES
[0084] A mixed solution of 5% (w / v) methacryloyl silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The concentration of methacryloyl silk fibroin in component A solution was adjusted to 5% (w / v), and its composition, preparation method, and usage method were the same as those in Example 19. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0085] A mixed solution of 10% (w / v) methacryloyl silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 3% (w / v) methacryloyl silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The concentration of methacryloyl silk fibroin in component solution B was adjusted to 3% (w / v), and the composition, preparation method, and usage method were the same as those in Example 19. EXAMPLES
[0086] A mixed solution of 10% (w / v) methacryloyl silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 5% (w / v) methacryloyl silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The hemopexin activity in component solution A was adjusted to 500 IU / mL, and the composition, preparation method, and usage method were the same as those in Example 19. EXAMPLES
[0087] A mixed solution of 10% (w / v) methacryloyl silk fibroin-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) methacryloyl silk fibroin-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. The concentration of fibrinogen in component B solution was adjusted to 3% (w / v), and its composition, preparation method, and usage method were the same as those in Example 19. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2. EXAMPLES
[0088] A mixed solution of 3% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. In this example, the photosensitive material in components A and B was methacryloyl chitosan, the concentration of methacryloyl chitosan in component A solution was 3% (w / v), and the concentration of methacryloyl chitosan in component B solution was 1% (w / v), except that the preparation method and the use method were the same as those in Example 9. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:1. EXAMPLES
[0089] A mixed solution of 2% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The concentration of methacryloyl chitosan in component solution A was adjusted to 2% (w / v), and the composition, preparation method, and usage method were the same as those in Example 25. EXAMPLES
[0090] A mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The concentration of methacryloyl chitosan in component A solution was adjusted to 1% (w / v), and the composition, preparation method, and usage method were the same as those in Example 25. In the gel obtained in this manner, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0091] A mixed solution of 3% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 0.5% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The concentration of methacryloyl chitosan in component solution B was adjusted to 0.5% (w / v), and the composition, preparation method, and usage method were the same as those in Example 25. EXAMPLES
[0092] A mixed solution of 3% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The hemopexin activity in component solution A was adjusted to 500 IU / mL, but the composition, preparation method, and usage method were the same as those in Example 25. EXAMPLES
[0093] A mixed solution of 3% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 1% (w / v) methacryloyl chitosan-0.1% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. The concentration of fibrinogen in component B solution was adjusted to 3% (w / v), and its composition, preparation method, and usage method were the same as those in Example 25. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2. EXAMPLES
[0094] A mixed solution of 20% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. In this example, the photosensitive material in components A and B was polyether F127 diacrylate, and the preparation method and usage method were the same as those in Example 9, except that the concentration of polyether F127 diacrylate in component A solution was 20% (w / v) and the concentration of polyether F127 diacrylate in component B solution was 10% (w / v). In the gel thus obtained, the volume ratio of fibrin crosslinks to photocrosslinks was 1:1. EXAMPLES
[0095] A mixed solution of 15% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The concentration of polyether F127 diacrylate in component solution A was adjusted to 15% (w / v), and the composition, preparation method, and usage method were the same as those in Example 31. EXAMPLES
[0096] A mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The concentration of polyether F127 diacrylate in component A solution was adjusted to 10% (w / v), and the composition, preparation method, and usage method were the same as those in Example 31. In the gel obtained in this manner, the volume ratio of fibrin crosslinking to photocrosslinking was 2:1. EXAMPLES
[0097] A mixed solution of 20% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 5% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. The composition, preparation method, and usage method of the component B solution were the same as those of Example 31, except that the concentration of polyether F127 diacrylate in the component B solution was adjusted to 5% (w / v). EXAMPLES
[0098] A mixed solution of 20% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-500 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component solution B. The hemopexin activity in component solution A was adjusted to 500 IU / mL, but the composition, preparation method, and usage method were the same as those in Example 31. EXAMPLES
[0099] A mixed solution of 20% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 10% (w / v) polyether F127 diacrylate-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-3% (w / v) fibrinogen was prepared as component B solution. The concentration of fibrinogen in component B solution was adjusted to 3% (w / v), and its composition, preparation method, and usage method were the same as those in Example 31. In the gel obtained in this way, the volume ratio of fibrin crosslinking to photocrosslinking was 1:2.
[0100] <Comparative Example 1> A lyophilized fibrin adhesive containing an enzyme reagent and a fibrinogen reagent (Wuguo Laishi, purchased from Shanghai Laishi Co., Ltd.) was used externally. According to the instruction manual, the enzyme reagent and the fibrinogen reagent were prepared in solution, mixed, and enzymatic cross-linking was carried out for about 1 s to obtain a fibrin adhesive with the microstructure shown in Figure 1.
[0101] <Comparative Example 2> The precursor solution of 9% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate was prepared in the same manner as the component A solution of Example 2, except that no hemopexin was added to the solution.
[0102] <Comparative Example 3> The mixed solution of 13% (w / v) methacryloylated gelatin-0.25% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate-1000 IU / mL hemopexin had the same ingredients and was prepared by the same method as the component A solution in Example 2.
[0103] <Comparative Example 4> The ingredients and preparation method of the mixed solution of 5% (w / v) methacryloylated gelatin-0.125% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate-5% (w / v) fibrinogen were the same as those in step (5) of Example 1.
[0104] <Comparative Example 5> A mixed solution of 30% (w / v) methacryloylated sericin, 0.5% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, and 1000 IU / mL hemopexin was prepared as component solution A, and a mixed solution of 20% (w / v) methacryloylated sericin, 0.5% (w / v) lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, and 5% (w / v) fibrinogen was prepared as component solution B. In this comparative example, the photosensitive material in components A and B was methacryloylated sericin, the concentration of methacryloylated sericin in component A solution was 30% (w / v), the concentration of lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate was 0.5% (w / v), and the concentration of methacryloylated sericin in component B solution was 20% (w / v), and the concentration of lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate was 0.5% (w / v), and the preparation method was the same as in Example 9. In the gel thus obtained, the volume ratio of fibrin crosslinks to photocrosslinks was 1:1.
[0105] <Comparative Example 6> A mixed solution of 10% (w / v) methacryloylated dextran-0.25% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-1000 IU / mL hemopexin was prepared as component A solution, and a mixed solution of 10% (w / v) methacryloylated dextran-0.125% (w / v) lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate-5% (w / v) fibrinogen was prepared as component B solution. In this comparative example, the photosensitive material in components A and B was methacryloylated dextran, the concentration of methacryloylated dextran in component A solution was 10% (w / v), and the concentration of methacryloylated dextran in component B solution was 5% (w / v), except that the preparation method was the same as in Example 9. In the gel thus obtained, the volume ratio of fibrin crosslinks to photocrosslinks was 1:1.
[0106] Performance Testing In order to confirm the performance of the doubly cross-linked fibrin gels obtained in Examples 1 to 36 and the hydrogels of Comparative Examples 1 to 6, a performance test of gelation time, an adhesive strength test, and an animal hemostatic experiment were carried out on each of them as described below.
[0107] Gel Time Test What to detect: Above Examples 1 to 36 and Comparative Examples 1 to 6 Detection method: Rheological analysis was performed for Examples 1-36 and Comparative Examples 1-6 to compare the gelation time, and the results are shown in Table 1. Specific operating method: Dynamic rheological experiments were performed at 37°C using a HAAKE RS6000 opto-rheometer with parallel plate (P20 TiL, diameter 20 mm) geometry. Time sweep oscillatory tests of the hydrogels of Examples 1-36 and Comparative Examples 1-6 were performed at 5% strain and 1 Hz frequency for 300 seconds. Strain sweeps were performed on the pregelling solutions to verify the linear response. The gelation point is determined when the torsional modulus (G') exceeds the loss modulus (G'').
[0108] Adhesive Strength Test Above Examples 1 to 36 and Comparative Examples 1 to 6 Detection method: Specific operation: Pigskin was cut into a rectangle of 40 mm x 20 mm, and two pieces of pigskin were bonded together using 500 μl of Examples 1 to 36 and Comparative Examples 1 to 6. The mixed solutions of A and B components of Examples 1 to 36 and the precursor solutions of Comparative Examples 2 to 6 were irradiated with blue light of the same wavelength band for 60 s. The adhesive strength was then tested at a strain rate of 1 mm / min. The microstructure of the gel formed after photocrosslinking of the precursor solution of Comparative Example 2 is shown in FIG. 2. The microstructure of the gel formed after photocrosslinking of the mixed solution in Example 1 is shown in FIG. 3. The reading when the gel was peeled off from the pigskin was recorded and taken as the adhesive strength (kPa). The detection results are shown in Table 1.
[0109] Hemostatic effect test What to detect: Examples 1, 9, 14, 19, 25, and 31 of the present invention, and Comparative Examples 1 to 6 Detection method: Rabbit liver surface 1 cm incision bleeding model: After anesthetizing a New Zealand white rabbit, the abdomen was exposed and fixed to the operating table, the abdomen was incised in the midline to expose the liver, and a bleeding model of 1 cm x 0.5 cm was created on the liver. Using weighed filter paper, the A component and B component of Examples 1, 9, 14, 19, 25, and 31, the obtained mixed solution and the precursor solution of Comparative Examples 1 to 6 were injected by the injection method described in step (7) of Example 1, and the bleeding site was covered as a hemostatic material until the bleeding stopped (among these, each of the Examples of the present invention and Comparative Examples 2 to 6 covered the bleeding site and treated it with blue light of the same wavelength band). The bleeding time and blood loss were recorded, and the results are shown in Table 1, Figure 4, and Figure 5.
[0110] [Table 1]
[0111] Values for time to hemostasis and blood loss are expressed as (mean ± standard deviation). Result analysis:
[0112] As can be seen from Fig. 1, in the fibrin adhesive of Comparative Example 1, only fibrin crosslinking forms a network structure. As can be seen from Fig. 2, after the precursor solution of Comparative Example 2 is irradiated, only methacryloylated gelatin is photo-crosslinked to form a porous structure. As can be seen from Fig. 3, the mixed solution of component A and component B in Example 1 of the present invention can have both a fibrin crosslinked network structure and a methacryloylated gelatin crosslinked porous structure after irradiation, and a continuous three-dimensional fibrin network structure is distributed throughout the channels of the formed crosslinked porous structure of methacryloylated gelatin. As can be seen from Table 1, the gelation times of Examples 1 to 36 ranged from 1 to 3 s, and for the same photosensitive material, the gelation time increased with increasing photocrosslinking ratio; on the other hand, for all types of photosensitive materials selected in Examples 1 to 36, the gelation time at a certain double crosslinking ratio was significantly shorter than that of Comparative Examples 2 to 4 (the gelation time of Comparative Example 2 was 8 s, the gelation time of Comparative Example 3 was 9 s, and the gelation time of Comparative Example 4 was 14 s).
[0113] As can be seen from Table 1, the adhesive strength of Examples 1 to 36 ranged from 82 to 132 kPa. With the same photosensitive material, the adhesive strength of the gel decreased as the concentration of the photosensitive material decreased; on the other hand, all types of photosensitive materials selected in Examples 1 to 36 had higher adhesive strengths at a certain double crosslinking ratio than those of each comparative example (Adhesive strength of Comparative Example 1 is 6 kPa, adhesive strength of Comparative Example 2 is 80 kPa, adhesive strength of Comparative Example 3 is 76 kPa, adhesive strength of Comparative Example 4 is 70 kPa, adhesive strength of Comparative Example 5 is 29 kPa, and adhesive strength of Comparative Example 6 is 45 kPa).
[0114] As can be seen from Table 1, Figures 4 and 5, the hemostasis times in Examples 1, 9, 14, 19, 25 and 31 were 6 s to 24 s, all of which were significantly shorter than the 40 s or more in Comparative Examples 1 to 6. The average blood loss in Examples 1, 9, 14, 19, 25 and 31 was 12 mg to 37 mg, which was significantly lower than the blood loss of 90 mg or more in Comparative Examples 1 to 6.
[0115] In short, when the double cross-linked fibrin gel of the present invention is applied to a bleeding wound, it immediately (about 1s) forms a fibrin clot, which plays a role in "preliminarily" closing the wound and blocking blood outflow. In addition, the enzyme in the fibrin clot converts fibrinogen in the blood into a clot, which plays an efficient procoagulation effect. In addition, the photosensitive material forms a photosensitive gel under light excitation, and the photosensitive gel has a strong adhesive force to wet tissue and plays a "strong" wound closing effect. The interaction between the fibrin cross-linked structure and the photo-cross-linked structure gives both the function of preliminarily closing the wound and the function of strong tissue adhesion, thereby achieving an excellent hemostatic effect.
[0116] The above is a detailed description of the specific embodiments of the present invention. However, the present invention is not limited to the specific embodiments, and any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention do not affect the essence of the present invention, and are all within the scope of protection of the claims of the present invention.
Claims
1. A double cross-linked fibrin gel capable of achieving rapid on-site hemostasis at a bleeding wound, A solid hydrogel composed of a network structure having a closing function and a network structure having an adhesive function, the meshwork having a closing function is a three-dimensional fibrin meshwork, the meshwork having an adhesive function is a three-dimensional photosensitive gel meshwork, each of the photosensitive gel meshwork channels has a set of the fibrin meshworks therein, each set of the fibrin meshworks is generally continuous, and the three-dimensional fibrin meshwork is generally randomly distributed across the surface and interior of the solid hydrogel; the volume ratio of the three-dimensional fibrin network to the three-dimensional photosensitive gel network is 0.5 to 3; A double-crosslinked fibrin gel, characterized in that the fibrin meshwork is formed prior to the formation of a photosensitive gel, the fibrin meshwork is formed by enzymatic crosslinking of fibrinogen, the photosensitive gel is formed by photocrosslinking of a photosensitive material, and the photosensitive material is a polymer composite material system containing a methacryloylated high molecular weight polymer or a derivative thereof, a polyacrylate high molecular weight polymer or a derivative thereof, or a methacryloylated high molecular weight polymer or a polyacrylate high molecular weight polymer.
2. The double crosslinked fibrin gel according to claim 1, characterized in that the methacryloylated high molecular polymer or derivative thereof is any one or a mixture of two or more selected from the group consisting of methacryloylated gelatin or a derivative thereof, methacryloylated hyaluronic acid or a derivative thereof, methacryloylated sodium alginate or a derivative thereof, methacryloylated silk fibroin or a derivative thereof, methacryloylated chitosan or a derivative thereof, and methacryloylated carboxymethyl chitosan or a derivative thereof.
3. 2. The double cross-linked fibrin gel according to claim 1, wherein the photosensitive material is methacryloylated gelatin or a derivative thereof, or methacryloylated silk fibroin or a derivative thereof.
4. 2. The double cross-linked fibrin gel according to claim 1, wherein the high molecular weight polymer of polyacrylates or a derivative thereof is selected from the group consisting of polyether diacrylate or a derivative thereof, and polyethylene glycol diacrylate or a derivative thereof.
5. The polymer composite material system containing the methacryloylated polymer may be a methacryloylated gelatin-polyvinyl alcohol system, a methacryloylated gelatin-polyurethane system, a methacryloylated gelatin-polylactic acid system, a methacryloylated gelatin-cellulose system, a methacryloylated hyaluronic acid-polyvinyl alcohol system, a methacryloylated hyaluronic acid-polyurethane system, a methacryloylated hyaluronic acid-polylactic acid system, a methacryloylated hyaluronic acid-cellulose system, a methacryloylated sodium alginate-polyvinyl alcohol system, a methacryloylated sodium alginate-polyurethane system, a methacryloylated sodium alginate-polylactic acid system, a methacryloylated sodium alginate-cellulose system, a methacryloylated silk fibroin ...
2. The double crosslinked fibrin gel according to claim 1, wherein the double crosslinked fibrin gel is one or more selected from the group consisting of a methacryloylated silk fibroin-polyurethane system, a methacryloylated silk fibroin-polylactic acid system, a methacryloylated silk fibroin-cellulose system, a methacryloylated chitosan-polyvinyl alcohol system, a methacryloylated chitosan-polyurethane system, a methacryloylated chitosan-polylactic acid system, a methacryloylated chitosan-cellulose system, a methacryloylated carboxymethyl chitosan-polyvinyl alcohol system, a methacryloylated carboxymethyl chitosan-polyurethane system, a methacryloylated carboxymethyl chitosan-polylactic acid system, and a methacryloylated carboxymethyl chitosan-cellulose system.
6. 2. The double cross-linked fibrin gel according to claim 1, wherein the fibrinogen is any one of human fibrinogen, bovine fibrinogen, and porcine fibrinogen.
7. 1. A raw material composition for preparing a rapid hemostatic dual cross-linking fibrin adhesive on-site by mixing at a bleeding wound, comprising: The composition A includes a composition A and a composition B, the composition A includes 10 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, the composition B includes 5 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen, the mass ratio of the composition A to the composition B being 1.4:10 to 14:1, the photosensitive material is a polymer composite material system including a methacryloylated high molecular weight polymer or a derivative thereof, a high molecular weight polymer of polyacrylates or a derivative thereof, or a methacryloylated high molecular weight polymer or a high molecular weight polymer of polyacrylates, the methacryloylated high molecular weight polymer or a derivative thereof being methacryloylated gelatin or a derivative thereof, a methacryloylated hyaluronic acid ... the enzyme is any one selected from human thrombin, recombinant human thrombin, bovine thrombin, porcine thrombin, and hemocoagulase; the dual cross-linked fibrin adhesive is a solid hydrogel composed of both a three-dimensional fibrin meshwork and a three-dimensional photosensitive gel meshwork, wherein each of the photosensitive gel meshwork channels has a set of the fibrin meshworks therein, each set of the fibrin meshworks being continuous as a whole, and the three-dimensional fibrin meshwork being present in a disordered manner across the surface and interior of the solid hydrogel as a whole.
8. 8. The raw material composition of claim 7, wherein the parts by weight of the photosensitive material in composition A is greater than the parts by weight of the photosensitive material in composition B.
9. 8. The raw material composition according to claim 7, wherein a mass ratio of said composition A to said composition B is 1.4:1 to 1.4:
10.
10. The raw material composition according to claim 7, wherein composition A comprises 80 to 200 parts by weight of a photosensitive material, 1 to 3 parts by weight of a photoinitiator, 0.14 to 0.28 parts by weight of an enzyme, and 1.11 to 8.88 parts by weight of a water-soluble inorganic calcium salt, and composition B comprises 30 to 100 parts by weight of a photosensitive material, 1 to 2 parts by weight of a photoinitiator, and 30 to 50 parts by weight of fibrinogen.
11. 8. The raw material composition according to claim 7, wherein the high molecular weight polymer of polyacrylates or a derivative thereof is selected from the group consisting of polyether diacrylate or a derivative thereof, and polyethylene glycol diacrylate or a derivative thereof.
12. The polymer composite material system containing the methacryloylated polymer may be a methacryloylated gelatin-polyvinyl alcohol system, a methacryloylated gelatin-polyurethane system, a methacryloylated gelatin-polylactic acid system, a methacryloylated gelatin-cellulose system, a methacryloylated hyaluronic acid-polyvinyl alcohol system, a methacryloylated hyaluronic acid-polyurethane system, a methacryloylated hyaluronic acid-polylactic acid system, a methacryloylated hyaluronic acid-cellulose system, a methacryloylated sodium alginate-polyvinyl alcohol system, a methacryloylated sodium alginate-polyurethane system, a methacryloylated sodium alginate-polylactic acid system, a methacryloylated sodium alginate-cellulose system, a methacryloylated silk fibroin- 8. The raw material composition according to claim 7, which is any one or more selected from polyvinyl alcohol, methacryloylated silk fibroin-polyurethane, methacryloylated silk fibroin-polylactic acid, methacryloylated silk fibroin-cellulose, methacryloylated chitosan-polyvinyl alcohol, methacryloylated chitosan-polyurethane, methacryloylated chitosan-polylactic acid, methacryloylated chitosan-cellulose, methacryloylated carboxymethyl chitosan-polyvinyl alcohol, methacryloylated carboxymethyl chitosan-polyurethane, methacryloylated carboxymethyl chitosan-polylactic acid, and methacryloylated carboxymethyl chitosan-cellulose.
13. The raw material composition according to any one of claims 7 to 12, characterized in that the photosensitive material is methacryloylated gelatin or a derivative thereof, or methacryloylated silk fibroin or a derivative thereof.
14. The raw material composition according to any one of claims 7 to 12, characterized in that the photoinitiator is any one or more compositions selected from lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, ethyl 2,4,6-trimethylbenzoylphenylphosphinate, 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one, methyl 2-benzoylbenzoate, 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)butanone, and 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide].
15. 13. The raw material composition according to any one of claims 7 to 12, wherein the fibrinogen is any one selected from the group consisting of human fibrinogen, bovine fibrinogen, and porcine fibrinogen.
16. 13. The raw material composition according to claim 7, wherein the water-soluble inorganic calcium salt is calcium chloride, calcium nitrate, or calcium sulfate.
17. The raw material composition according to any one of claims 7 to 12, characterized in that the raw material composition is in the form of a freeze-dried powder, an injection, a sponge, or a granule.
18. the steps of preparing a mixed solution by dissolving a photosensitive material and a photoinitiator in a solvent, mixing the mixed solution with a solution containing hemopexin and calcium ions to obtain a first precursor solution, controlling a concentration ratio of the photosensitive material, the photoinitiator, the enzyme, and the calcium ions in the first precursor solution to 10-200:1-3:0.14-0.28:1.11-8.88, and controlling a storage time of the first precursor solution in a room temperature environment to less than 30 minutes; and mixing the mixed solution with a solution containing fibrinogen to obtain a second precursor solution, controlling a concentration ratio of the photosensitive material, the photoinitiator, and the fibrinogen in the second precursor solution to 5-100:1-2:30-50, and obtaining a liquid raw material composition containing the first precursor solution and the second precursor solution, The method for preparing a raw material composition according to any one of claims 7 to 12, wherein the photosensitive material is a polymer composite material system containing a methacryloylated high molecular weight polymer or a derivative thereof, a polyacrylate high molecular weight polymer or a derivative thereof, or a methacryloylated high molecular weight polymer or a polyacrylate high molecular weight polymer, and the methacryloylated high molecular weight polymer or a derivative thereof is any one or a mixture of two or more selected from methacryloylated gelatin or a derivative thereof, methacryloylated hyaluronic acid or a derivative thereof, methacryloylated sodium alginate or a derivative thereof, methacryloylated silk fibroin or a derivative thereof, methacryloylated chitosan or a derivative thereof, and methacryloylated carboxymethyl chitosan or a derivative thereof.
19. The liquid raw material composition is further treated by a freeze-drying method to obtain a solid raw material composition, 20. The method of claim 18, wherein the solid source composition is a lyophilized powder, a sponge, or a granule.
20. 20. The method of claim 18, wherein the concentration of the photosensitive material in the first precursor solution is controlled to be higher than 0.5% (w / v) and the concentration of the photosensitive material in the second precursor solution is controlled to be lower than the concentration of the photosensitive material in the first precursor solution.
21. in particular, Step 1) of preparing a first mixed solution by dissolving a photosensitive material and a photoinitiator in a solvent, and controlling the concentration ratio of the photosensitive material to the photoinitiator to be 10-200:1-3 and the concentration of the photosensitive material to be 0.5%-30% (w / v); 2) preparing a second mixed solution by dissolving a photosensitive material and a photoinitiator in a solvent, and controlling the concentration ratio of the photosensitive material to the photoinitiator to be 5-100:1-2 and the concentration of the photosensitive material to be lower than that of the first mixed solution described in 1); 3) mixing the first mixed solution prepared in 1) with a solution containing an enzyme and calcium ions to obtain a first precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, the enzyme, and the calcium ions to 10-200: 1-3: 0.14-0.28: 1.11-8.88; 19. The method of claim 18, further comprising: step 4) mixing the second mixed solution prepared in step 2) with a solution containing fibrinogen to obtain a second precursor solution, and controlling the concentration ratio of the photosensitive material, the photoinitiator, and the fibrinogen to be 5-100:1-2:30-50.
22. The solution containing the enzyme and calcium ions is prepared by adding a solvent and a water-soluble inorganic calcium salt solution to the enzyme, dissolving it completely and forming Ca 2+ The enzyme activity in the resulting solution is 500 IU to 2000 IU / ml, Ca 2+ The method according to any one of claims 18 and 21, characterized in that the concentration is controlled to be 60 to 100 mmol / L.
23. 22. The method according to claim 18, wherein the concentration of fibrinogen in the fibrinogen-containing solution is 5% to 10% (w / v).
24. The method according to any one of claims 18 or 21, characterized in that the concentration of the photosensitive material in the first precursor solution is controlled to be 1% to 30% (w / v).
25. 22. The method according to claim 18 or 21, wherein the enzyme activity in the first precursor solution is controlled to be 200 IU / ml or more.
26. 22. The method according to claim 18, wherein the concentration of calcium ions in the first precursor solution is controlled to be 20 mmol / L or more.
27. 22. The method according to claim 18, wherein the concentration of the photosensitive material in the second precursor solution is controlled to be between 1% and 10% (w / v) and equal to or lower than the concentration of the photosensitive material in the first precursor solution.
28. 22. The method of claim 18 or 21, wherein the concentration of fibrinogen in the second precursor solution is controlled to be 3% (w / v) or higher.
29. A kit for preparing the double cross-linked fibrin gel according to any one of claims 1 to 6, comprising: A kit comprising a first precursor reagent and a second precursor reagent, the first precursor reagent containing 10-200 parts by weight of a photosensitive material, 1-3 parts by weight of a photoinitiator, 0.14-0.28 parts by weight of an enzyme, and 3.33-5.55 parts by weight of a water-soluble inorganic calcium salt, the second precursor reagent containing 5-100 parts by weight of a photosensitive material, 1-2 parts by weight of a photoinitiator, and 30-50 parts by weight of fibrinogen, the mass ratio of the first precursor reagent to the second precursor reagent being 1.4:10-14:1, the photosensitive material being a polymer composite material system containing a methacryloylated high molecular weight polymer or a derivative thereof, a polyacrylate high molecular weight polymer or a derivative thereof, or a methacryloylated high molecular weight polymer or a polyacrylate high molecular weight polymer, and the enzyme being any one selected from human thrombin, recombinant human thrombin, bovine thrombin, porcine thrombin, and hemocoagulase.
30. 30. The kit of claim 29, wherein the mass ratio of the first precursor reagent to the second precursor reagent is 1.4:1 to 1.4:
10.
31. 30. The kit of claim 29, wherein the first precursor reagent contains 80-200 parts by weight of a photosensitive material, 1-3 parts by weight of a photoinitiator, 0.14-0.28 parts by weight of an enzyme, and 3.33-5.55 parts by weight of a water-soluble inorganic calcium salt, and the second precursor reagent contains 30-100 parts by weight of a photosensitive material, 1-2 parts by weight of a photoinitiator, and 30-50 parts by weight of fibrinogen.
32. The kit according to claim 29, characterized in that the methacryloylated high molecular weight polymer or its derivative is any one or a mixture of two or more selected from methacryloylated gelatin or a derivative thereof, methacryloylated hyaluronic acid or a derivative thereof, methacryloylated sodium alginate or a derivative thereof, methacryloylated silk fibroin or a derivative thereof, methacryloylated chitosan or a derivative thereof, and methacryloylated carboxymethyl chitosan or a derivative thereof.
33. 30. The kit of claim 29, wherein the photosensitive material is methacryloylated gelatin or a derivative thereof, or methacryloylated silk fibroin or a derivative thereof.
34. The kit according to claim 29, characterized in that the high molecular weight polymer of the polyacrylates or its derivatives is selected from polyether diacrylate or its derivatives, or polyethylene glycol diacrylate or its derivatives.
35. The polymer composite material system containing the methacryloylated polymer may be a methacryloylated gelatin-polyvinyl alcohol system, a methacryloylated gelatin-polyurethane system, a methacryloylated gelatin-polylactic acid system, a methacryloylated gelatin-cellulose system, a methacryloylated hyaluronic acid-polyvinyl alcohol system, a methacryloylated hyaluronic acid-polyurethane system, a methacryloylated hyaluronic acid-polylactic acid system, a methacryloylated hyaluronic acid-cellulose system, a methacryloylated sodium alginate-polyvinyl alcohol system, a methacryloylated sodium alginate-polyurethane system, a methacryloylated sodium alginate-polylactic acid system, a methacryloylated sodium alginate-cellulose system, a methacryloylated silk fibroin- The kit according to claim 29, characterized in that the kit is any one or more selected from polyvinyl alcohol, methacryloylated silk fibroin-polyurethane, methacryloylated silk fibroin-polylactic acid, methacryloylated silk fibroin-cellulose, methacryloylated chitosan-polyvinyl alcohol, methacryloylated chitosan-polyurethane, methacryloylated chitosan-polylactic acid, methacryloylated chitosan-cellulose, methacryloylated carboxymethyl chitosan-polyvinyl alcohol, methacryloylated carboxymethyl chitosan-polyurethane, methacryloylated carboxymethyl chitosan-polylactic acid, and methacryloylated carboxymethyl chitosan-cellulose.
36. The kit according to any one of claims 29 to 35, characterized in that the photoinitiator is any one or more compositions selected from lithium phenyl(2,4,6-trimethylbenzoyl)phosphinate, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, ethyl 2,4,6-trimethylbenzoylphenylphosphinate, 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one, methyl 2-benzoylbenzoate, 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)butanone, or 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide].
37. The kit according to any one of claims 29 to 35, wherein the fibrinogen is any one selected from human fibrinogen, bovine fibrinogen, and porcine fibrinogen.
38. The kit according to any one of claims 29 to 35, characterized in that the water-soluble inorganic calcium salt is selected from calcium chloride, calcium nitrate, or calcium sulfate.
39. The kit according to any one of claims 29 to 35, wherein the first precursor reagent and / or the second precursor reagent further comprise an auxiliary material and / or an additive, the auxiliary material being one or more selected from glycine, arginine hydrochloride, sodium citrate, sucrose, and sodium chloride, and the additive being one or more selected from growth factors, interleukins, vitamins, and silver ions.
40. 40. The kit of claim 39, wherein the growth factor is one or more selected from platelet growth factor, epidermal growth factor, or fibroblast growth factor.
41. 40. The kit of claim 39, wherein the interleukin is one or more selected from interleukin 2, interleukin 6, or interleukin 8.
42. 40. The kit of claim 39, wherein the vitamin is one or more selected from vitamin B, vitamin C, vitamin E, or vitamin K.
43. 36. The kit of any one of claims 29 to 35, further comprising an individually packaged formulation solvent, the formulation solvent being any one or more of a mixture of phosphate buffer solution, HEPES biological buffer, 0.9% sodium chloride solution, calcium chloride solution, or deionized water.
44. The kit according to any one of claims 29 to 35, further comprising an instruction manual for the kit.
45. A method for performing on-site rapid hemostasis on a bleeding wound using the kit according to any one of claims 29 to 35, comprising the steps of: The method includes: preparing the first precursor reagent and the second precursor reagent of the kit into an injectable solution using a preparation solvent, uniformly injecting or spraying the first precursor reagent and the second precursor reagent into the bleeding wound; and then irradiating the bleeding wound with light in the wavelength range of 290 to 480 nm for 10 to 60 s to rapidly form a solid hydrogel as a coagulation hemostatic material in situ at the bleeding wound.
46. 46. The method of claim 45, wherein the bleeding wound comprises organ bleeding caused by accidental trauma or during surgery, the organ being the liver, spleen, kidney, gastrointestinal tract, heart, or skin.
Citation Information
Patent Citations
Visible light curing biological tissue binding material based on natural polymer as well as preparation method and application of visible light curing biological tissue binding material
CN114392387A
Hemostatic tissue sealants
US6162241A
Double-crosslinkable two-liquid-type bioink composition and method for manufacturing tissue-like structure using same
WO2020231191A1
